Portage Biotech Toekomstige groei

Future criteriumcontroles 0/6

Portage Biotech zal naar verwachting dalen met 81% per jaar. De winst per aandeel zal naar verwachting groeien met 104.3% per jaar.

Belangrijke informatie

81.0%

Groei van de winst

104.3%

Groei van de winst per aandeel

Biotechs winstgroei	28.3%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	11 Mar 2024

Recente toekomstige groei-updates

Recent updates

Portage Biotech GAAP EPS of -$0.13

Aug 29

Portage Biotech rises after getting full ownership of its anti-cancer agonist platform

Jul 20

Portage Biotech acquires Tarus Therapeutics, a developer of adenosine receptor antagonists

Jul 06

Winst- en omzetgroeiprognoses

NasdaqCM:PRTG - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
3/31/2026	N/A	-18	N/A	N/A	1
3/31/2025	N/A	-16	N/A	N/A	1
6/30/2024	N/A	-71	-13	-13	N/A
3/31/2024	N/A	-75	-14	-14	N/A
12/31/2023	N/A	-145	-16	-16	N/A
9/30/2023	N/A	-113	-15	-15	N/A
6/30/2023	N/A	-109	-13	-13	N/A
3/31/2023	N/A	-105	-12	-12	N/A
12/31/2022	N/A	-17	-10	-10	N/A
9/30/2022	N/A	-14	-9	-9	N/A
6/30/2022	N/A	-16	-7	-7	N/A
3/31/2022	N/A	-17	-7	-7	N/A
12/31/2021	N/A	-21	-5	-5	N/A
9/30/2021	N/A	-19	-5	-5	N/A
6/30/2021	N/A	-18	-5	-5	N/A
3/31/2021	N/A	-16	-4	-4	N/A
12/31/2020	N/A	-6	-4	-4	N/A
9/30/2020	N/A	-6	-4	-4	N/A
6/30/2020	N/A	-5	-3	-3	N/A
3/31/2020	N/A	-5	-4	-4	N/A
12/31/2019	N/A	-6	-3	-3	N/A
9/30/2019	N/A	-5	-3	-3	N/A
6/30/2019	N/A	-4	-2	-2	N/A
3/31/2019	N/A	-3	-1	-1	N/A
12/31/2018	N/A	124	-1	-1	N/A
9/30/2018	N/A	124	-1	-1	N/A
6/30/2018	N/A	124	-1	-1	N/A
3/31/2018	N/A	124	N/A	-1	N/A
12/31/2017	N/A	-10	N/A	2	N/A
9/30/2017	N/A	-16	N/A	2	N/A
6/30/2017	N/A	19	N/A	2	N/A
3/31/2017	N/A	16	N/A	-1	N/A
12/31/2016	N/A	24	N/A	-6	N/A
9/30/2016	N/A	27	N/A	-7	N/A
6/30/2016	N/A	-8	N/A	-8	N/A
3/31/2016	N/A	-6	N/A	-6	N/A
12/31/2015	N/A	-6	N/A	-6	N/A
9/30/2015	N/A	-3	N/A	-5	N/A
6/30/2015	N/A	-3	N/A	-3	N/A
3/31/2015	N/A	-3	N/A	-3	N/A
12/31/2014	N/A	-4	N/A	-3	N/A
9/30/2014	N/A	-3	N/A	-3	N/A
6/30/2014	N/A	-3	N/A	-2	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat PRTG de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat PRTG de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat PRTG de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van PRTG naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er wordt verwacht dat PRTG volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van PRTG naar verwachting over 3 jaar hoog zal zijn

Portage Biotech Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 22% to US$140

Price target decreased by 16% to US$16.00

Recent updates

Price target decreased by 22% to US$140

Portage Biotech Inc. Announces Chief Financial Officer Changes

Portage Biotech Inc. announced delayed 20-F filing

Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives

New major risk - Financial position

New major risk - Market cap size

Portage Biotech Inc. Presents Updates on its iNKT and Adenosine Programs at the Society for Immunotherapy of Cancer's 38th Annual Meeting

New major risk - Revenue and earnings growth

New major risk - Share price stability

Price target decreased by 16% to US$16.00

Portage Biotech Inc. Announces First Patient Dosed in Phase 1A Trial of Portage-6 in Select Solid Tumors

Portage Biotech Reports Updated Interim Data for Lead Inkt Engager, Port-2, in A Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer At the 2023 American Society for Clinical Oncology (Asco) Annual Meeting

Portage Biotech Inc. Presents Updated Data on the Phase 1/2 Trial Evaluating Port-2 At the Society for Immunotherapy of Cancer’S (Sitc) 37Th Annual Meeting

Portage Biotech Inc., Annual General Meeting, Nov 10, 2022

Portage Biotech Inc. Provides Research and Development Update

Portage Biotech GAAP EPS of -$0.13

Portage Biotech Inc. Announces Leadership Updates

Portage Biotech rises after getting full ownership of its anti-cancer agonist platform

Portage Biotech Inc. (NasdaqCM:PRTG) signed an agreement to acquire Tarus Therapeutics, Inc. for $53.3 million.

Portage Biotech Inc. (NasdaqCM:PRTG) signed an agreement to acquire Tarus Therapeutics, Inc.

Portage Biotech acquires Tarus Therapeutics, a developer of adenosine receptor antagonists

Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting

Portage Biotech Inc. Provides an Update on Its Clinical Development Programs and Announces Its Development Goals for the Remainder of 2022

Portage Biotech Announces Executive Changes

Portage Biotech Inc. Highlights First Patient Dosed in Imp-Mel Study of Port-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (Nsclc)

Portage Biotech Inc. has completed a Follow-on Equity Offering in the amount of $23 million.

Portage Biotech Inc. Highlights Safety and Survival Data from Intensity Therapeutics' It-01 Study of Int230-6 (Port-1) At Asco 2021 Annual Meeting

Juvenescence Ltd. acquired Portage pharmaceuticals Ltd from Portage Biotech Inc. (NasdaqCM:PRTG).

Portage Biotech's Common Shares Deleted from Other OTC

Portage Biotech Inc. announced that it has received $6.98145 million in funding

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven